Cohort Study of Antihyperglycemic Medication and Pancreatic Cancer Patients Survival
Abstract
:1. Introduction
2. Material and Methods
2.1. Data Sources
2.2. Study Population
2.3. Exposure
2.4. Diabetes Treatment Guidelines
2.5. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Arnold, M.; Abnet, C.C.; Neale, R.E.; Vignat, J.; Giovannucci, E.L.; McGlynn, K.A.; Bray, F. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 2020, 159, 335–349.e15. [Google Scholar] [CrossRef]
- McGuigan, A.; Kelly, P.; Turkington, R.C.; Jones, C.; Coleman, H.G.; McCain, R.S. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J. Gastroenterol. 2018, 24, 4846–4861. [Google Scholar] [CrossRef]
- International Diabetes Federation. IDF Diabetes Atlas—9th ed. Diabetes Atlas. 2019. Available online: http://www.diabetesatlas.org/ (accessed on 13 February 2020).
- Stern, R.J.; Murphy, E.J. Metformin as initial oral therapy in type 2 diabetes. JAMA 2015, 313, 2484–2485. [Google Scholar] [CrossRef]
- Schneider, M.B.; Matsuzaki, H.; Haorah, J.; Ulrich, A.; Standop, J.; Ding, X.; Adrian, T.E.; Pour, P.M. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001, 120, 1263–1270. [Google Scholar] [CrossRef]
- Wang, L.-W. Metformin induces apoptosis of pancreatic cancer cells. World J. Gastroenterol. 2008, 14, 7192–7198. [Google Scholar] [CrossRef] [Green Version]
- Kisfalvi, K.; Moro, A.; Sinnett-Smith, J.; Eibl, G.; Rozengurt, E.; Krisztina, K.; Aune, M.; James, S.-S.; Guido, E.; Rozengurt, E. Metformin inhibits the growth of human pancreatic cancer xenografts. Pancreas 2013, 42, 781–785. [Google Scholar] [CrossRef] [Green Version]
- Cifarelli, V.; Lashinger, L.M.; Devlin, K.L.; Dunlap, S.M.; Huang, J.; Kaaks, R.; Pollak, M.N.; Hursting, S.D. Metformin and rapamycin reduce pancreatic cancer growth in obese prediabetic mice by distinct MicroRNA-regulated mechanisms. Diabetes 2015, 64, 1632–1642. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baron, B.; Wang, Y.; Maehara, S.-I.; Maehara, Y.; Kuramitsu, Y.; Nakamura, K. Resistance to gemcitabine in the pancreatic cancer cell line KLM1-R reversed by metformin action. Anticancer Res. 2015, 35, 1941–1949. [Google Scholar] [PubMed]
- Kisfalvi, K.; Eibl, G.; Sinnett-Smith, J.; Rozengurt, E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 2009, 69, 6539–6545. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cusi, K.; Consoli, A.; DeFronzo, R.A. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 1996, 81, 4059–4067. [Google Scholar]
- Shaw, R.J.; Lamia, K.A.; Vasquez, D.; Koo, S.-H.; Bardeesy, N.; Depinho, R.A.; Montminy, M.; Cantley, L.C. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Sciences 2005, 310, 1642–1646. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rozengurt, E.; Sinnett-Smith, J.; Kisfalvi, K. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: A novel target for the antidiabetic drug metformin in pancreatic cancer. Clin. Cancer Res. 2010, 16, 2505–2511. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kalender, A.; Selvaraj, A.; Kim, S.Y.; Gulati, P.; Brûlé, S.; Viollet, B.; Kemp, B.E.; Bardeesy, N.; Dennis, P.; Schlager, J.J.; et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010, 11, 390–401. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ben Sahra, I.; Regazzetti, C.; Robert, G.; Laurent, K.; Le Marchand-Brustel, Y.; Auberger, P.; Tanti, J.-F.; Giorgetti-Peraldi, S.; Bost, F. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011, 71, 4366–4372. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sinnett-Smith, J.; Kisfalvi, K.; Kui, R.; Rozengurt, E. Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: Dependence on glucose concentration and role of AMPK. Biochem. Biophys. Res. Commun. 2013, 430, 352–357. [Google Scholar] [CrossRef] [Green Version]
- Nair, V.; Sreevalsan, S.; Basha, R.; Abdelrahim, M.; Abudayyeh, A.; Hoffmann, A.R.; Safe, S. Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and ras activity in pancreatic cancer. J. Boil. Chem. 2014, 289, 27692–27701. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nair, V.; Pathi, S.; Jutooru, I.; Sreevalsan, S.; Basha, R.; Abdelrahim, M.; Samudio, I.; Safe, S. Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors. Carcinogenesis 2013, 34, 2870–2879. [Google Scholar] [CrossRef] [Green Version]
- Gou, S.; Cui, P.; Li, X.; Shi, P.; Liu, T.; Wang, C. Low concentrations of metformin selectively inhibit CD133(þ) cell proliferation in pancreatic cancer and have anticancer action. PLoS ONE 2013, 8, e63969. [Google Scholar] [CrossRef]
- Lonardo, E.; Cioffi, M.; Sancho, P.; Sanchez-Ripoll, Y.; Trabulo, S.M.; Dorado, J.; Balic, A.; Hidalgo, M.; Heeschen, C. Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PLoS ONE 2013, 8, e76518. [Google Scholar] [CrossRef] [Green Version]
- Nakamura, M.; Ogo, A.; Yamura, M.; Yamaguchi, Y.; Nakashima, H. Metformin suppresses sonic hedgehog expression in pancreatic cancer cells. Anticancer Res. 2014, 34, 1765–1769. [Google Scholar]
- Tanaka, R.; Tomosugi, M.; Horinaka, M.; Sowa, Y.; Sakai, T. Metformin causes G1-Phase arrest via down-regulation of MiR-221 and enhances TRAIL sensitivity through DR5 Up-Regulation in pancreatic cancer cells. PLoS ONE 2015, 10, e0125779. [Google Scholar] [CrossRef] [Green Version]
- Dulskas, A.; Patasius, A.; Linkeviciute-Ulinskiene, D.; Zabuliene, L.; Urbonas, V.; Smailyte, G. Metformin increases cancer specific survival in colorectal cancer patients-National cohort study. Cancer Epidemiol. 2019, 62, 101587. [Google Scholar] [CrossRef] [PubMed]
- Dulskas, A.; Patasius, A.; Linkeviciute-Ulinskiene, D.; Zabuliene, L.; Smailyte, G. A cohort study of antihyperglycemic medication exposure and survival in patients with gastric cancer. Aging 2019, 11, 7197–7205. [Google Scholar] [CrossRef] [PubMed]
- Tang, G.H.; Satkunam, M.; Pond, G.R.; Steinberg, G.R.; Blandino, G.; Schünemann, H.J.; Muti, P. Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis. Cancer Epidemiol. Biomark. Prev. 2018, 27, 627–635. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Richards, K.A.; Liou, J.-I.; Cryns, V.L.; Downs, T.M.; Abel, E.J.; Jarrard, D.F. Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy. J. Urol. 2018, 200, 1256–1263. [Google Scholar] [CrossRef] [PubMed]
- Cerullo, M.; Gani, F.; Chen, S.Y.; Canner, J.; Pawlik, T.M. Metformin use is associated with improved survival in patients undergoing resection for pancreatic cancer. J. Gastrointest. Surg. 2016, 20, 1572–1580. [Google Scholar] [CrossRef] [PubMed]
- Amin, S.; Mhango, G.; Lin, J.J.; Aronson, A.; Wisnivesky, J.; Boffetta, P.; Lucas, A.L. Metformin improves survival in patients with pancreatic ductal adenocarcinoma and pre-existing diabetes: A propensity score analysis. Am. J. Gastroenterol. 2016, 111, 1350–1357. [Google Scholar] [CrossRef] [Green Version]
- Chaiteerakij, R.; Petersen, G.M.; Bamlet, W.; Chaffee, K.G.; Zhen, D.B.; Burch, P.A.; Leof, E.R.; Roberts, L.R.; Oberg, A.L. Metformin use and survival of patients with pancreatic cancer: A cautionary lesson. J. Clin. Oncol. 2016, 34, 1898–1904. [Google Scholar] [CrossRef]
- Reni, M.; Dugnani, E.; Cereda, S.; Belli, C.; Balzano, G.; Nicoletti, R.; Liberati, D.; Pasquale, V.; Scavini, M.; Maggiora, P.; et al. (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase 2 Trial. Clin. Cancer Res. 2015, 22, 1076–1085. [Google Scholar] [CrossRef] [Green Version]
- Kordes, S.; Pollak, M.N.; Zwinderman, A.H.; Mathot, R.A.; Weterman, M.J.; Beeker, A.; Punt, C.J.; Richel, D.J.; Wilmink, J.W. Metformin in patients with advanced pancreatic cancer: A double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2015, 16, 839–847. [Google Scholar] [CrossRef]
- Bray, F.; Ferlay, J.; Laversanne, M.; Brewster, D.H.; Mbalawa, C.G.; Kohler, B.; Piñeros, M.; Steliarova-Foucher, E.; Swaminathan, R.; Antoni, S.; et al. Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration. Int. J. Cancer 2015, 137, 2060–2071. [Google Scholar] [CrossRef] [PubMed]
- Navickas, R.; Visockiene, Z.; Puronaitė, R.; Rukšėnienė, M.; Kasiulevičius, V.; Jurevičienė, E. Prevalence and structure of multiple chronic conditions in Lithuanian population and the distribution of the associated healthcare resources. Eur. J. Intern. Med. 2015, 26, 160–168. [Google Scholar] [CrossRef] [PubMed]
- Lietuvos Respublikos Sveikatos Apsaugos Ministro Įsakymas Dėl cukrinio diabeto ambulatorinio gydymo kompensuojamaisiais vaistais tvarkos aprašo patvirtinimo, 2012 m. vasario 28 d. Nr. V-159. Valstybės Žinios 2012, 27, 1228.
- Toriola, A.T.; Luo, S.; Thomas, T.S.; Drake, B.F.; Chang, S.-H.; Sanfilippo, K.M.; Carson, K.R. Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus. Cancer Epidemiol. Biomark. Prev. 2019, 29, 169–175. [Google Scholar] [CrossRef] [PubMed]
- Ambe, C.M.; Mahipal, A.; Fulp, J.; Chen, L.; Malafa, M.P. Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A single-institution experience and review of the literature. PLoS ONE 2016, 11, e0151632. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hwang, A.L.; Haynes, K.; Hwang, W.-T.; Yang, Y.-X. Metformin and survival in pancreatic cancer. Pancreas 2013, 42, 1054–1059. [Google Scholar] [CrossRef] [Green Version]
- Jang, W.I.; Kim, M.-S.; Kang, S.H.; Jo, A.J.; Kim, Y.J.; Tchoe, H.J.; Park, C.M.; Kim, H.J.; Choi, J.A.; Choi, H.J.; et al. Association between metformin use and mortality in patients with type 2 diabetes mellitus and localized resectable pancreatic cancer: A nationwide population-based study in korea. Oncotarget 2017, 8, 9587–9596. [Google Scholar] [CrossRef]
- Kozak, M.M.; Anderson, E.M.; Von Eyben, R.; Pai, J.S.; Poultsides, G.A.; Visser, B.C.; Norton, J.A.; Koong, A.C.; Chang, D.T. Statin and metformin use prolongs survival in patients with resectable pancreatic cancer. Pancreas 2016, 45, 64–70. [Google Scholar] [CrossRef]
- Sadeghi, N.; Abbruzzese, J.L.; Yeung, S.-C.J.; Hassan, M.; Li, D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin. Cancer Res. 2012, 18, 2905–2912. [Google Scholar] [CrossRef] [Green Version]
- Choi, Y.; Kim, T.-Y.; Oh, D.-Y.; Lee, K.-H.; Han, S.-W.; Im, S.-A.; Kim, T.-Y.; Bang, Y.-J. The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. Cancer Res. Treat. 2016, 48, 171–179. [Google Scholar] [CrossRef]
- Zhou, P.-T.; Li, B.; Liu, F.-R.; Zhang, M.-C.; Wang, Q.; Li, Y.-Y.; Xu, C.; Liu, Y.-H.; Yao, Y.; Li, D. Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: A systematic review and meta-analysis. Oncotarget 2017, 8, 25242–25250. [Google Scholar] [CrossRef] [PubMed]
- Wan, G.; Sun, X.; Li, F.; Wang, X.-B.; Li, C.; Li, H.; Yu, X.; Cao, F. Survival Benefit of Metformin Adjuvant Treatment for Pancreatic Cancer Patients: A Systematic Review and Meta-Analysis. Cell. Physiol. Biochem. 2018, 49, 837–847. [Google Scholar] [CrossRef] [PubMed]
- Xin, W.; Fang, L.; Fang, Q.; Zheng, X.; Huang, P. Effects of metformin on survival outcomes of pancreatic cancer patients with diabetes: A meta-analysis. Mol. Clin. Oncol. 2017, 8, 483–488. [Google Scholar] [CrossRef] [PubMed]
- Dong, Y.-W.; Shi, Y.-Q.; He, L.-W.; Cui, X.-Y.; Su, P.-Z. Effects of metformin on survival outcomes of pancreatic cancer: A meta-analysis. Oncotarget 2017, 8, 55478–55488. [Google Scholar] [CrossRef] [Green Version]
- Li, X.; Li, T.; Liu, Z.; Gou, S.; Wang, C. The effect of metformin on survival of patients with pancreatic cancer: A meta-analysis. Sci. Rep. 2017, 7, 5825. [Google Scholar] [CrossRef]
- Zhou, D.-C.; Gong, H.; Tan, C.-Q.; Luo, J.-Q. Prognostic significance of anti-diabetic medications in pancreatic cancer: A meta-analysis. Oncotarget 2017, 8, 62349–62357. [Google Scholar] [CrossRef] [Green Version]
- Lee, S.H.; Yoon, S.H.; Lee, H.S.; Chung, M.J.; Park, J.Y.; Park, S.W.; Song, S.Y.; Chung, J.B.; Bang, S.; Information, P.E.K.F.C. Can metformin change the prognosis of pancreatic cancer? Retrospective study for pancreatic cancer patients with pre-existing diabetes mellitus type 2. Dig. Liver Dis. 2016, 48, 435–440. [Google Scholar] [CrossRef]
- Jeon, C.Y.; Pandol, S.J.; Goodman, M.T. Abstract 2173: Survival time in pancreatic cancer patients with metabolic syndrome varies by use of insulin and statins. Epidemiology 2014, 74, 2173. [Google Scholar]
Antihyperglycemic Medications | |||||||
---|---|---|---|---|---|---|---|
Variable | Sulfonylurea | Metformin | Sulfonylurea and Metformin | Metformin and Other Medications | Insulin | Other Medications | p Value |
Total | 114 | 75 | 155 | 67 | 26 | 17 | |
Gender | |||||||
Male | 49 (43.0) | 33 (44.0) | 60 (38.7) | 32 (47.8) | 13 (50.0) | 8 (47.1) | 0.78 |
Female | 65 (57.0) | 42 (56.0) | 95 (61.3) | 35 (52.2) | 13 (50.0) | 9 (52.9) | |
Age at diagnosis | |||||||
<60 | 6 (5.3) | 8 (10.7) | 21 (13.5) | 7 (10.4) | 6 (23.0) | 3 (17.7) | 0.009 |
60–69 | 26 (22.8) | 16 (21.3) | 43 (27.7) | 28 (41.8) | 8 (30.8) | 9 (52.9) | |
70–79 | 48 (42.1) | 36 (48.0) | 62 (40.0) | 22 (32.8) | 8 (30.8) | 4 (23.5) | |
80+ | 34 (29.8) | 15 (20.0) | 29 (18.7) | 10 (14.9) | 4 (15.4) | 1 (5.9) | |
TNM stage | |||||||
I | 4 (3.5) | 5 (6.7) | 11 (7.1) | 3 (4.5) | 3 (11.5) | 1 (5.9) | 0.94 |
II | 16 (14.0) | 12 (16.0) | 26 (16.8) | 15 (22.4) | 4 (15.4) | 5 (29.4) | |
III | 17 (14.9) | 13 (17.3) | 21 (13.5) | 10 (14.9) | 2 (7.7) | 3 17.6) | |
IV | 61 (53.6) | 33 (44.0) | 72 (46.5) | 28 (41.8) | 14 (53.9) | 7 (41.2) | |
Missing | 16 (14.0) | 12 (160) | 25 (16.1) | 11 (16.4) | 3 (11.5) | 1 (5.9) | |
Histology | |||||||
Adenocarcinoma | 49 (43.0) | 43 (57.3) | 86 (55.5) | 42 (62.7) | 13 (50.0) | 12 (70.6) | 0.17 |
Other | 12 (10.5) | 3 (4.0) | 6 (3.9) | 5 (7.5) | 2 (7.7) | 1 (5.9) | |
Neuroendocrine | 4 (3.5) | 1 (1.3) | 10 (6.4) | 1 (1.5) | 2 (7.7) | 1 (5.9) | |
Not specified | 49 (43.) | 28 (37.4) | 53 (34.2) | 19 (28.3) | 9 (34.6) | 3 (17.6) |
Variable | Multivariate-Adjusted HR * (95% CI) | p-Value |
---|---|---|
Gender | ||
Male | 1.00 | ref. |
Female | 0.86 (0.70–1.05) | 0.13 |
Age at diagnosis | ||
<60 | 1.00 | ref. |
60–69 | 1.02 (0.72–1.43) | 0.91 |
70–79 | 1.44 (1.02–2.04) | 0.04 |
80+ | 2.07 (1.40–3.06) | <0.001 |
TNM stage | ||
I | 1.00 | ref. |
II | 0.99 (0.62–1.59) | 0.97 |
III | 1.43 (0.88–2.31) | 0.15 |
IV | 2.80 (1.81–4.35) | <0.001 |
Missing | 1.30 (0.80–2.10) | 0.29 |
Histology | ||
Adenocarcinoma | 1.00 | ref. |
Other | 0.91 (0.60–1.37) | 0.66 |
Neuroendocrine | 0.27 (0.15–0.48) | <0.001 |
Not specified | 1.26 (1.01–1.58) | 0.04 |
Antihyperglycemic medications | ||
Sulfonylurea | 1.00 | ref. |
Metformin | 0.80 (0.59–1.09) | 0.15 |
Sulfonylurea and metformin | 0.79 (0.61–1.02) | 0.08 |
Metformin and other medications | 0.94(0.68–2.29) | 0.69 |
Insulin | 1.31 (0.83–2.04) | 0.24 |
Other medications | 0.61 (0.36–1.03) | 0.07 |
Variable | Multivariate-Adjusted HR * (95% CI) | p-Value |
---|---|---|
By metformin use | ||
Non-users | 1.00 | ref. |
Users | 0.85 (0.70–1.04) | 0.12 |
By metformin cumulative dose | ||
Non-users | 1.00 | ref. |
<920.000 | 0.94 (0.72–1.21) | 0.62 |
920.000–1.840.000 | 0.87 (0.67–1.12) | 0.28 |
>1.840.000 | 0.76 (0.58–0.99) | 0.04 |
By antihyperglycemic medication ** | ||
Sulfonylurea | 1.00 | ref. |
Metformin | 0.74 (0.54–1.02) | 0.07 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Dulskas, A.; Patasius, A.; Linkeviciute-Ulinskiene, D.; Zabuliene, L.; Smailyte, G. Cohort Study of Antihyperglycemic Medication and Pancreatic Cancer Patients Survival. Int. J. Environ. Res. Public Health 2020, 17, 6016. https://doi.org/10.3390/ijerph17176016
Dulskas A, Patasius A, Linkeviciute-Ulinskiene D, Zabuliene L, Smailyte G. Cohort Study of Antihyperglycemic Medication and Pancreatic Cancer Patients Survival. International Journal of Environmental Research and Public Health. 2020; 17(17):6016. https://doi.org/10.3390/ijerph17176016
Chicago/Turabian StyleDulskas, Audrius, Ausvydas Patasius, Donata Linkeviciute-Ulinskiene, Lina Zabuliene, and Giedre Smailyte. 2020. "Cohort Study of Antihyperglycemic Medication and Pancreatic Cancer Patients Survival" International Journal of Environmental Research and Public Health 17, no. 17: 6016. https://doi.org/10.3390/ijerph17176016